Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer

Απλή σελίδα τεκμηρίου
dc.contributor.authorFountzilas, G.en
dc.contributor.authorPapadimitriou, C.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorNicolaides, C.en
dc.contributor.authorStathopoulos, G.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorEkonomopoulos, T.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorDimopoulos, A. M.en
dc.date.accessioned2015-11-24T19:23:43Z
dc.date.available2015-11-24T19:23:43Z
dc.identifier.issn0030-2414-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/22356
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/mortalityen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDisease-Free Survivalen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectHumansen
dc.subjectMethotrexate/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/administration & dosageen
dc.subjectRisken
dc.titleDose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast canceren
heal.abstractDose-dense sequential chemotherapy appears to be a promising approach in the management of patients with operable breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. From February 1995 until September 1997, 49 women with histologically confirmed breast cancer and > or =10 involved axillary nodes were treated postoperatively with three cycles of epirubicin (110 mg/m(2)) followed by three cycles of paclitaxel (250 mg/m(2) in a 3-hour infusion) followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m(2), methotrexate 57 mg/m(2), fluorouracil 840 mg/m(2); E-T-CMF). All cycles were repeated every 2 weeks with G-CSF support. Ovarian ablation with monthly injections of triptorelin for 1 year was performed in premenopausal patients and tamoxifen was prescribed for 5 years to all women with positive receptor status after the completion of chemotherapy. A total of 456 cycles of chemotherapy were administered, 363 (80%) of them at full dose. Forty-seven (96%) patients received all 9 cycles of chemotherapy. Relative dose intensity of epirubicin was 0.98, of paclitaxel 0.97, of cyclophosphamide 0.99, of methotrexate 0.98 and of fluorouracil 0.99. Grade 3--4 toxicities included anemia (8%), leukopenia (8%), peripheral neuropathy (6%), neutropenia (4%), thrombocytopenia (4%), stomatitis (2%), diarrhea (2%), fatigue (2%) and hypersensitivity reaction (2%). Febrile neutropenia occurred in 2 patients. Alopecia was universal. After a median follow-up of 3 years, 11 women (22%) relapsed and 4 (8%) died. The 3-year actuarial disease-free survival rate was 72% and the 3-year overall survival rate 90%. The E-T-CMF regimen is well tolerated, as adjuvant treatment, in patients with operable breast cancer with promising activity and deserves further evaluation in phase III studies.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11340372-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000055321&Ausgabe=228144&ProduktNr=223857&filename=000055321.pdf-
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2001-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ